Inflammation and prostate cancer

Future Oncology

Volumn 4, Issue 5, 2008, Pages 637-645

  Vasto, Sonya ^a   Carruba, Guiseppe ^b   Candore, Giuseppina ^b   Italiano, Emilio ^c   Di Bona, Danilo ^a,d   Caruso, Calogero ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b ARNAS Civico   (Italy)

^c Villa Sofia Hospital   (Italy)

^d CNR   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTANOLONE PROPIONATE; CYCLOOXYGENASE 2; ESTRADIOL; ESTROGEN; ONCOPROTEIN; PROSTAGLANDIN; PROTEIN NKX3.1; TESTOSTERONE; UNCLASSIFIED DRUG;

ANDROGEN THERAPY; CARCINOGENESIS; DISEASE ASSOCIATION; DRUG MEGADOSE; GENE FUNCTION; GENE OVEREXPRESSION; GENE TARGETING; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; HOMOZYGOSITY; HORMONAL CARCINOGENESIS; HUMAN; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; RISK FACTOR; SEXUAL BEHAVIOR; SEXUALLY TRANSMITTED DISEASE; STEROID BLOOD LEVEL; STEROID RELEASE;

ANIMALS; GONADAL STEROID HORMONES; HUMANS; INFLAMMATION; MALE; PROSTATIC NEOPLASMS;

EID: 55249096718     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/14796694.4.5.637     Document Type: Review

References (83)

1. De Marzo AM, Coffey DS, Nelson WG: New concepts in tissue specificity for prostate cancer and benign prostatic hyperplasia. Urology 53, 29-39 (1999).
2. Jemal A, Siegel R, Ward E et al.: Cancer statistics, 2007. CA Cancer J. Clin. 57(1), 43-66 (2007).
3. Boring CC, Squires TS, Health CW Jr: Cancer statistics for African Americans. CA Cancer J. Clin. 42, 7-17 (1992).
4. Hsing AW, Chokkalingam AP: Prostate cancer epidemiology. Front. Biosci. 11, 1388-1413 (2006).
5. Kolonel LN: Cancer incidence among Filipinos in Hawaii and the Philippines. Natl. Cancer Inst. Monogr. 69, 93-98 (1985).
6. Tominaga S: Cancer incidence in Japanese in Japan, Hawaii, and western United States. Natl. Cancer Inst. Monogr. 69, 83-92 (1985).
7. Stellman SD, Wang QS: Cancer mortality in Chinese immigrants to New York City. Comparison with Chinese in Tianjin and with United States-born whites. Cancer 73, 1270-1275 (1994).
8. Cook LS, Goldoft M, Schwartz SM et al.: Incidence of adenocarcinoma of the prostate in Asian immigrants to the United States and their descendants. J. Urol. 161, 152-155 (1999).
9. Wynder EL, Fujita Y, Harris RE et al.: Comparative epidemiology of cancer between the United States and Japan. A second look. Cancer 67, 746-763 (1991).
10. Liu MC, Hai A, Huang AT: Cancer epidemiology in the Far East - contrast with the United States. Oncology (Williston Park, NY) 7, 99-110 (1993).
11. Tymchuk CN, Barnard RJ, Ngo TH et al.: Role of testosterone, estradiol, and insulin in diet- and exercise-induced reductions in serum-stimulated prostate cancer cell growth in vitro. Nutr. Cancer 42, 112-116 (2002).
12. Caruso C, Lio D, Cavallone L et al.: Aging, longevity, inflammation, and cancer. Ann. NY Acad. Sci. 1028, 1-13 (2004).
13. Vasto S, Carruba G, Lio D et al.: Inflammation, ageing and cancer. Mech. Ageing Dev. PMID: 18671998 (2008) (Epub ahead of print).
14. Allavena P, Garlanda C, Borrello, MG, Sica A, Mantovani A: Pathways connecting inflammation and cancer. Curr. Opin. Genet. Dev. 1, 3-10 (2008).
15. Dennis LK, Lynch CF, Torner JC: Epidemiologic association between prostatitis and prostate cancer. Urology 60, 78-83 (2002).
16. Hochreiter WW, Nadler RB, Koch AE et al.: Evaluation of the cytokines interleukin 8 and epithelial neutrophil activating peptide 78 as indicators of inflammation in prostatic secretions. Urology 56(6), 1025-1029 (2000).
17. Fujita K, Ewing CM, Sokoll LJ et al.: Cytokine profiling of prostatic fluid from cancerous prostate glands identifies cytokines associated with extent of tumor and inflammation. Prostate 68, 872-882 (2008).
18. Franks LM: Atrophy and hyperplasia in the prostate proper. J. Pathol. Bacteriol. 68, 617-621 (1954).
19. Bennett BD, Richardson PH, Gardner WA: Histopathology and Cytology of Prostatitis. In: Prostate Diseases. Lepor H, Lawson RK (Eds). WB Saunders Company, PA, USA, 399-414 (1993).
20. De Matzo AM, Meeker AK, Zha S et al.: Human prostate cancer precursors and pathobiology. Urology 62, 55-62 (2003).
21. Putzi MJ, De Matzo AM: Morphologic transitions between proliferative inflammatory atrophy and high-grade prostatic intraepithelial Neoplasia Urology 56, 828-832 (2000).
22. Shah R, Mucci NR, Amin A, Macoska JA, Rubin MA: Postatrophic hyperplasia of the prostate gland: neoplastic precursor or innocent bystander? Am. J. Pathol. 158, 1767-1773 (2001).
23. Dennis LK, Lynch CF, Torner JC: Epidemiologic association between prostatitis and prostate cancer. Urology 60, 78-83 (2002).
24. Roberts RO, Bergstralh EJ, Bass SE, Lieber MM, Jacobsen SJ: Prostatitis as a risk factor for prostate cancer. Epidemiology 15, 93-99 (2004).
25. Montironi R, Mazzucchelli R, Scarpelli M: Precancerous lesions and conditions of the prostate: from morphological and biological characterization to chemoprevention. Ann. NY Acad. Sci. 963, 169-184 (2002).
26. Gerstenbluth RE, Seftel AD, MacLennan GT et al.: Distribution of chronic prostatitis in radical prostatectomy specimens with up-regulation of bcl-2 in areas of inflammation. J. Urol. 167, 2267-2270 (2002).
27. Cohen RJ, Shannon BA, McNeal JE, Shannon T, Garrett KL: Propionibacterium acnes associated with inflammation in radical prostatectomy specimens: a possible link to cancer evolution? J. Urol. 173, 1969-1974 (2005).
28. De Matzo AM, Marchi VL, Epstein JI, Nelson WG: Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am. J. Pathol. 155, 1985-1992 (1999).
29. Dempke W, Rie C, Grothey A et al.: Cyclooxygenase-2: a novel target for cancerchemotherapy? J. Cancer Res. Clin. Oncol. 127, 411-417 (2001).
30. DeWitt DL: Prostaglandin endoperoxide synthase: regulation of enzyme expression. Biochim Biohys. Acta 1083, 121-134 (1991).
31. Wang W, Bergh A, Damber JE: Chronic inflammation in benign prostate hyperplasia is associated with focal upregulation of cyclooxygenase-2, Bcl-2, and cell proliferation in the glandular epithelium. Prostate 61, 60-72 (2004).
32. Hawk ET, Viner JL, Dannenberg A et al.: COX-2 in cancer - a player that's defining the rules. J. Natl. Cancer Inst. 17(94), 545-546 (2002).
33. Smith WL, DeWitt DL, Garavito RM: Cyclooxygenases: structural, cellular, and molecular biology. Annu. Rev. Biochem. 69, 145-182 (2000).
34. Dannenberg AJ, Lippman SM, Mann JR et al.: Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. J. Clin. Oncol. 23, 254-266 (2005).
35. Ghosh R, Garcia GE, Crosby K et al.: Regulation of Cox-2 by cyclic AMP response element binding protein in prostate cancer: potential role for nexrutine. Neoplasia 9, 893-899 (2007).
36. Chen H, Nandi AK, Li X et al.: NKX-3.1 interacts with prostate-derived Ets factor and regulates the activity of the PSA promoter. Cancer Res. 15 (62), 338-340 (2002).
37. Kim MJ, Cardiff RD, Desai N et al.: Cooperativity of Nkx3.1 and Pten loss of function in a mouse model of prostate carcinogenesis. Proc. Natl. Acad. Sci. USA 99, 2884-2889 (2002).
38. Ornstein DK, Cinquanta M, Weiler S et al.: Expression studies and mutational analysis of the androgen regulated homeobox gene NKX3.1 in benign and malignant prostate epithelium. J. Urol. 165, 1329-1334 (2001).
39. Li H, Tai BC: RNASEL gene polymorphisms and the risk of prostate cancer: a meta-analysis. Clin. Cancer Res. 12, 5713-5719 (2006).
40. Summers K, Crespi B: Molecular evolution of the prostate cancer susceptibility locus RNASEL: evidence for positive selection. Infect. Genet. Evol. 3, 297-301 (2008).
41. Casey G, Neville PJ, Plummer SJ et al.: RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases. Nat. Genet. 32, 581-583 (2002).
42. Nakazato H, Suzuki K, Matsui H et al.: Role of genetic polymorphisms of the RNASEL gene on familial prostate cancer risk in a Japanese population. Br. J. Cancer 89, 691-696 (2003).
43. El-Ornar EM, Ng MT, Hold GL: Polymorphisms in Toll-like receptor genes and risk of cancer. Oncogene 27, 244-252 (2008).
44. Kundu SD, Lee C, Billips BK et al.: The toll-like receptor pathway: a novel mechanism of infection-induced carcinogenesis of prostate epithelial cells. Prostate 68, 223-229 (2008).
45. Balistreri CR, Candore G, Listí F et al.: Role of TLR4 polymorphisms in inflammatory responses: implications for unsuccessful aging. Ann. NY Acad. Sci. 1119, 203-207 (2007).
46. Candore G, Aquino A, Balistreri CR et al.: Inflammation, longevity, and cardiovascular diseases: role of polymorphisms of TLR4. Ann. NY Acad. Sci. 1067, 282-287 (2006).
47. McCarron SL, Edwards S, Evans PR et al.: Influence of cytokine gene polymorphisms on the development of prostate cancer. Cancer Res. 62, 3369-3372 (2002).
48. Sun J, Turner A, Xu J et al.: Genetic variability in inflammation pathways and prostate cancer risk. Urol. Oncol. 25, 250-259 (2007).
49. Dennis LK, Lynch CF, Torner JC: Epidemiologic association between prostatitis and prostate cancer. Urology 60, 78-83 (2002).
50. Hayes RB, Pattern LM, Strickler H et al.: Sexual behaviour, STDs and risks for prostate cancer. Br. J. Cancer 82, 718-725 (2000).
51. Strickler HD, Goedert J: Sexual behaviour and evidence for an infectious cause of prostate cancer. Epidemiol. Rev. 23, 144-151 (2001).
52. Dennis LK, Dawson DV. Meta-analysis of measures of sexual activity and prostate cancer. Epidemiology 13, 72-79 (2002).
53. Taylor ML, Mainous AG, Wells BJ: Prostate cancer and sexually transmitted diseases: a meta-analysis. Fam. Med. 37(7), 506-512 (2005).
54. Dennis LK, Dawson DV: Meta-analysis of measures of sexual activity and prostate cancer, Epidemiology 13(1), 72-79 (2002).
55. Strickler HD, Goedert JJ: Sexual behavior and evidence for an infectious cause of prostate cancer. Epidemiol. Rev. 23(1), 144-151 (2001).
56. Huggins C, Hodges CV: Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J. Urol. 168, 9-12 (2002).
57. Henderson BE, Ross RK, Pike MC et al.: Endogenous hormones as a major factor in human cancer. Cancer Res. 42, 3232-3239 (1982).
58. Guinan PD, Sadoughi W, Alsheik H et al.: Impotence therapy and cancer of the prostate. Am. J. Surg. 131, 599-600 (1976).
59. Roberts JT, Essenhigh DM: Adenocarcinoma of prostate in 40-year-old body-builder. Lancet 2(8509), 742 (1986).
60. Jackson JA, Waxman J, Spickerman AM: Prostatic complications of testosterone replacement therapy. Arch. Intern. Med. 149, 2365-2366 (1989).
61. Garnick MB, Fair WR: Combating prostate cancer. Sci. Am. 279, 74-83 (1998).
62. Carruba G, Leake RE, Rinaldi F et al.: Steroid-growth factor interaction in human prostate cancer. 1. Short-term effects of transforming growth factors on growth of human prostate cancer cells. Steroids 59, 412-420 (1994).
63. Castagnetta LA, Carruba G: Human prostate cancer: a direct role for oestrogens. Ciba Found. Symp. 191, 269-286 (1995).
64. Leav I, Merk FB, Kwan PW et al.: Androgen-supported estrogen-enhanced epithelial proliferation in the prostates of intact Noble rats. Prostate 15, 23-40 (1989).
65. Wang Y, Hayward SW, Donjacour AA et al.: Sex hormone-induced carcinogenesis in Rb-deficient prostate tissue. Cancer Res. 60, 6008-6017 (2000).
66. Cunha GR, Wang YZ, Hayward SW et al.: Estrogenic effects on prostatic differentiation and carcinogenesis. Reprod. Fertil. Dev. 13, 285-296 (2001).
67. Carruba G: Estrogen and prostate cancer: an eclipsed truth in an androgen-dominated scenario. J. Cell. Biochem. 102, 899-911 (2007).
68. Negri-Cesi P, Poletti A, Colciago A et al.: Presence of 5α-reductase isozymes and aromatase in human prostate cancer cells and in benign prostate hyperplastic tissue. Prostate 34, 283-291 (1998).
69. Weber KS, Jacobson NA, Setchell KD et al.: Brain arornatase and 5α-reductase, regulatory behaviors and testosterone levels in adult rats on phytoestrogen diets. Proc. Soc. Exp. Biol. Med. 221, 131-135 (1999).
70. Steers WD: 5α-reductase activity in the prostate. Urology 58, 17-24 (2001).
71. Santen RJ, Santner SJ, Pauley RJ et al.: Estrogen production via the aromatase enzyme in breast carcinoma: which cell type is responsible? J. Steroid Biochem. Mol. Biol. 61, 267-271 (1997).
72. Jarred RA, Cancilla B, Prins GS et al.: Evidence that estrogens directly alter androgen-regulated prostate development. Endocrinology 141, 3471-3477 (2000).
73. Brueggemeier RW, Quinn AL, Parrett ML et al.: Correlation of aromatase and cyclooxygenase gene expression in human breast cancer specimens. Cancer Lett. 140, 27-35 (1999).
74. Zhao Y, Agarwal VR, Mendelson CR et al.: Estrogen biosynthesis proximal to a breast tumor is stimulated by PGE2 via cyclic AMP, leading to activation of promoter II of the CYP19 (aromatase) gene. Endocrinology 137, 5739-5742 (1996).
75. Singh A, Purohit A, Ghilchik MW et al.: The regulation of aromatase activity in breast fibroblasts: the role of interleukin-6 and prostaglandin E2. Endocr. Relat. Cancer 6, 139-147 (1999).
76. Harris MT, Feldberg RS, Lau KM et al.: Expression of proinflammatory genes during estrogen-induced inflammation of the rat prostate. Prostate 44, 19-25 (2000).
77. Risbridger GP, Bianco JJ, Ellem SJ et al.: Oestrogens and prostate cancer. Endocr. Relat. Cancer 10, 187-191 (2003).
78. Bianco JJ, Handelsman DJ, Pedersen JS, Risbridger GP: Direct response of the routine prostate gland and seminal vesicles to estradiol. Endocrinology 143, 4922-4933 (2002).
79. Risbridger GP, Ellem SJ, McPherson SJ: Estrogen action on the prostate gland: a critical mix of endocrine and paracrine signaling. J. Mol. Endocrinol. 39, 183-188 (2007).
80. Bianco JJ, McPherson SJ, Wang H et al.: Transient neonatal exposure to estrogen deficient mice (Aromatase knockout) reduces prostate weight and induces inflammation in late life. Am. J. Pathol. 168, 1869-1878 (2006).
81. Prins GS, Birch L, Tang WY, Ho SM: Developmental estrogen exposures predispose to prostate carcinogenesis with aging. Reprod. Toxicol. 23, 374-382 (2007).
82. Prins GS, Birch L, Couse JF et al.: Estrogen imprinting of the developing prostate gland is mediated through stromal estrogen receptor α: studies with αERKO and PERKO mice. Cancer Res. 61, 6089-6097 (2001).
83. Hooshmand S, Soungdo Y, Lucas EA et al.: Genistein reduces the production of proinflammatory molecules in human chondrocytes. J. Nutr. Biochem. 18, 609-614 (2007).